TriSalus Life Sciences, Inc. (TLSI) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$9.81M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$8.41M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$9.01M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$7.33M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$9.81M | (m) | $11.41M | (m) | $82.00K* | -$10.13M* | $1.51M | $3.14M | (m) | $4.00K |
| 2026-03-31 | Reported | (m) | -$8.41M | (m) | $8.90M | (m) | $141.00K | -$6.48M | $1.23M | $3.22M | (m) | $4.00K |
| 2025-09-30 | Reported | (m) | -$9.01M | (m) | $11.57M | (m) | $216.00K* | -$3.71M* | $1.91M | $5.18M | (m) | $5.00K |
| 2025-06-30 | Reported | (m) | -$7.33M | (m) | $11.21M | (m) | -$93.00K* | -$7.32M* | $1.80M | $3.67M | (m) | -$3.00K |
| 2025-03-31 | Reported | (m) | -$7.33M | (m) | $9.17M | (m) | $754.00K | -$4.50M | $1.50M | $3.02M | (m) | $5.00K |
| 2024-09-30 | Reported | (m) | -$8.74M | (m) | $7.35M | (m) | $169.00K* | -$10.85M* | $1.00M | $4.22M | (m) | -$3.00K |
| 2024-06-30 | Reported | (m) | -$8.17M | (m) | $7.36M | (m) | $60.00K* | -$13.42M* | $912.00K | $4.67M | (m) | $7.00K |
| 2024-03-31 | Reported | (m) | -$11.67M | (m) | $6.46M | (m) | $66.00K | -$10.87M | $971.00K | $5.84M | (m) | $3.00K |
| 2023-09-30 | Reported | (m) | -$18.62M | (m) | $5.19M | (m) | $178.00K* | -$21.66M* | $589.00K | $9.51M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$11.43M | (m) | $4.61M | (m) | $31.00K* | -$9.24M* | $772.00K | $6.89M | (m) | $13.00K |
| 2023-03-31 | Reported | (m) | -$10.12M | (m) | $2.98M | (m) | $7.00K | -$10.50M | $662.00K | $5.64M | (m) | -$5.00K |
| 2022-09-30 | Reported | (m) | -$8.11M | (m) | $3.92M | (m) | (m) | -$22.88M* | $701.00K | $4.81M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$288.27K | (m) | (m) | (m) | (m) | -$696.75K* | (m) | (m) | (m) | $28.20K |
| 2022-03-31 | Reported | (m) | -$669.81K | (m) | (m) | (m) | (m) | -$425.95K | (m) | (m) | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$807.26K | (m) | (m) | (m) | (m) | -$365.14K* | (m) | (m) | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$783.92K | (m) | (m) | (m) | (m) | -$486.21K* | (m) | (m) | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$307.99K | (m) | (m) | (m) | (m) | -$205.85K | (m) | (m) | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$26.95M | (m) | $45.15M | (m) | $918.00K | -$18.01M | $6.96M | $14.96M | (m) | $7.00K |
| 2024-12-31 | Reported | (m) | -$36.16M | (m) | $29.43M | (m) | $345.00K | -$40.84M | $4.10M | $17.69M | (m) | $6.00K |
| 2023-12-31 | Reported | (m) | -$54.48M | (m) | $18.51M | (m) | $588.00K | -$50.58M | $2.60M | $29.84M | (m) | $9.00K |
| 2022-12-31 | Reported | (m) | -$36.44M | (m) | $12.40M | (m) | $655.00K | -$32.31M | $2.26M | $21.36M | (m) | $9.00K |
| 2021-12-31 | Reported | (m) | -$3.04M | (m) | (m) | (m) | (m) | -$1.74M | (m) | (m) | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |